XENE Q1 2025 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

$8M100.0% margin

Operating Income

-$73M-969.8% margin

Net Income

-$65M-867.3% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$743M

Total Liabilities

$39M

Stockholders' Equity

$704M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	$8M	-$599,000	+1352.1%
Operating Income	-$73M	-$59M	-23.2%
Net Income	-$65M	-$48M	-35.7%